Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00180284 · ClinicalTrials.gov registry record · Phase 3

SITELINE 2 Polyurethane

A Phase 3 study of Bradycardia, sponsored by Boston Scientific Corporation.

Completed
Registry status
Phase 3
Development phase
200
Enrollment target
1
Study location

NCT00180284 is a Phase 3 study of Bradycardia that has completed, run by Boston Scientific Corporation. The registered enrollment target is 200 participants, below the 4,406-participant average among 29 other Bradycardia trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00180284, a Phase 3 study of Bradycardia, has completed, sponsored by Boston Scientific Corporation.

COMPLETED
Registry status
Phase 3
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

The SITELINE 2 Polyurethane Clinical Investigation analyzed the safety and electrical performance of the SITELINE 2 Polyurethane pacing lead.

Conditions Studied

Interventions

  • DEVICE SITELINE 2 Polyurethane (pacing lead)

Study Locations (1)

Minnesota

  • Multiple Locations in the United States - Saint Paul

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2004-11
Est. Completion 2008-02
Phase Phase 3

Sponsor

Boston Scientific Corporation

280 total trials

What the Registry Record Tells You About NCT00180284

The ClinicalTrials.gov registry entry for NCT00180284 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,406-participant average among 29 other Bradycardia trials with a reported enrollment target (95% lower). The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Bradycardia appearing as the primary indexed condition, and to 1 intervention - of which SITELINE 2 Polyurethane (pacing lead) is the first listed.

NCT00180284 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT00180284 about?

NCT00180284 is a clinical study titled "SITELINE 2 Polyurethane". The SITELINE 2 Polyurethane Clinical Investigation analyzed the safety and electrical performance of the SITELINE 2 Polyurethane pacing lead.

What is the current status of trial NCT00180284?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2004-11. Estimated completion is 2008-02.

What conditions does trial NCT00180284 study?

This clinical trial studies the following conditions: Bradycardia.

What interventions are being tested in trial NCT00180284?

The interventions under investigation include: SITELINE 2 Polyurethane (pacing lead) (DEVICE).

Who is sponsoring clinical trial NCT00180284?

This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00180284 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bradycardia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.